AVEO Pharmaceuticals Inc

NASDAQ:AVEO  
5.40
+0.03 (+0.56%)
Other Pre-Announcement

Aveo Pharmaceuticals Q3 Loss Per Share $0.33

Published: 11/09/2020 22:32 GMT
Aveo Pharmaceuticals Inc (AVEO) - Aveo Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update.
Q3 Revenue $3.6 Million Versus $25.7 Million.
Q3 Loss per Share $0.33.
Q3 Revenue Estimate $2.8 Million -- Refinitiv Ibes Data (analyst estimates).
Q3 Earnings per Share Estimate $-0.24 -- Refinitiv Ibes Data (analyst estimates).
Av-380 Ind Submission Expected by Year-end; Phase 1 Clinical Study Planned for Q1 of 2021.
Aveo Pharmaceuticals- Believes Current Cash, Cash Equivalents and Marketable Securities, Other Revenue Would Allow Co to Fund Planned Operations Into 2022.